Article Text

Download PDFPDF
One step closer to personalised prescribing of antidepressants: using real-world data together with patients and clinicians' preferences
  1. Catherine Kernot1,
  2. Anneka Tomlinson2,
  3. Astrid Chevance3,
  4. Andrea Cipriani2
  1. 1 R&D Department, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
  2. 2 Department of Psychiatry, University of Oxford, Oxford, UK
  3. 3 METHODS Team, Center for Research in Epidemiology and Statistics, Sorbonne Paris Cité (CRESS- UMR 1153), Paris, France
  1. Correspondence to Professor Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Antidepressants for many decades have been shown to be an effective treatment for depressive disorder.1 Approximately 80% of people with depressive disorder in the UK will have been prescribed an antidepressant within the first year following diagnosis.2 Indeed, about 71 million prescriptions for antidepressants were issued in the UK in 2018—nearly twice as many as the previous decade.3 However, there remain important questions around the tolerability of antidepressant medication. It is well recognised that the side effects of antidepressants can be extremely debilitating and that unwanted symptoms associated with these medications are one of the main reasons for patients discontinuing treatment.4

There are many different antidepressant drugs available, recommended by guidelines, and thus commonly used in real-world clinical practice in patients with depressive disorder across the world. A large number of different side effects of antidepressant medication from different patient populations have been reported in randomised controlled trails.5 While we now have evidence from randomised trials informing us which specific side effects are experienced by patients taking antidepressants, and the frequency of these specific individual side effects, we have limited evidence from real-world patients as to which …

View Full Text


  • Contributors CK and ACi drafted the editorial. AT and ACh critically revised it. All authors approved the final version of the manuscript.

  • Funding ACi is supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR Research Professorship (grant RP-2017-08-ST2-006) and by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Patient consent for publication Not required.